Ftse Mib
33.186,89
0,00%
DAX
18.210,55
0,26%
S&P 500
5.482,87
0,09%
NASDAQ
17.858,68
0,30%
Bitcoin
61.582,19
-0,05%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Verona Pharma Plc (VRNA) Verona Pharma Plc (VRNA) Notizie

Verona Pharma Plc

VRNA
15,15
0,46 (3,13%)
28 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
26/6/202422:57GLOBEVerona Pharma Announces US FDA Approval of Ohtuvayre™..
10/5/202415:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/5/202414:53EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/5/202413:22EDGAR2Form 8-K - Current report
09/5/202413:18EDGAR2Form 8-K - Current report
09/5/202413:15GLOBEVerona Pharma Reports First Quarter 2024 Financial Results..
09/5/202413:00GLOBEVerona Pharma Announces $650 Million Strategic..
02/5/202408:00GLOBEVerona Pharma to Present Additional Analyses of Positive..
25/4/202408:00GLOBEVerona Pharma to Report First Quarter 2024 Financial Results..
08/3/202422:18EDGAR2Form PRE 14A - Other preliminary proxy statements
08/3/202403:40EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/3/202408:00GLOBEAndrew Fisher Joins Verona Pharma as General Counsel
29/2/202415:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202412:08EDGAR2Form 8-K - Current report
29/2/202408:00GLOBEVerona Pharma Reports Fourth Quarter and Full Year 2023..
15/2/202408:00GLOBEVerona Pharma to Report Fourth Quarter and Full Year 2023..
06/2/202400:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202400:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:19EDGAR2Form 144 - Report of proposed sale of securities
02/2/202412:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202412:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/2/202412:02EDGAR2Form 8-K - Current report
01/2/202408:00GLOBEMichael Austwick Joins Verona Pharma as Non-Executive..
03/1/202408:00GLOBEVerona Pharma to Present at 42nd Annual J.P. Morgan..
02/1/202412:02EDGAR2Form 8-K - Current report
02/1/202408:00GLOBEVerona Pharma enters into Debt Facility of up to $400..
18/12/202322:15EDGAR2Form 8-K - Current report
17/11/202308:00GLOBEVerona Pharma’s President and CEO David Zaccardelli Wins..
08/11/202308:00GLOBEVerona Pharma Announces November 2023 Investor Conference..
04/11/202301:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/11/202301:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202321:25EDGAR2Form 144 - Report of proposed sale of securities
02/11/202321:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202311:24EDGAR2Form 8-K - Current report
02/11/202308:04GLOBEVerona Pharma Reports Third Quarter 2023 Financial Results..
24/10/202322:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/10/202322:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/10/202308:00GLOBEVerona Pharma to Report Third Quarter 2023 Financial Results..
06/10/202308:00GLOBEVerona Pharma to Host Investor Update on Commercialization..
03/10/202308:00GLOBEVerona Pharma to Present Additional Analyses of Positive..
11/9/202312:02EDGAR2Form 8-K - Current report
11/9/202308:00GLOBEVerona Pharma Announces the US FDA has Accepted the New Drug..
06/9/202308:00GLOBEVerona Pharma to Present Additional Analysis of Phase 3..
05/9/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202322:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
01/9/202322:05EDGAR2Form 8-K - Current report
31/8/202308:00GLOBEChristina Ackermann Joins Verona Pharma as Non-Executive..
08/8/202303:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202303:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/8/202302:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 14,80 Min: 14,59 Max: 16,06
Chiusura: 14,69

La tua Cronologia

NASDAQ
VRNA
Verona Pharma
BIT
P1TVX9
NLBNPIT1TVX9 20240621 65
BIT
S32562
Societe Generale Effekten
BIT
UC1H25
Unicredit Bank
BOV
BRFS3M
BRF S/A ON
BIT
P21VA5
NLBNPIT21VA5 20241028 100
NASDAQ
CIICW
CIIG Merger
BIT
NSCIT4000500
Republic of Finland
COIN
MLGCGBP
BOV
BRIV3Q
ALFA INVEST ON
AQSE
XDNY.GB
Xtrackers IE Public
TG
A28W3Z
Klepierre
LSE
55OJ
Res.mort.7'a'4a
BIT
P20SE5
NLBNPIT20SE5 20240920 24
BIT
UC1C00
Unicredit Bank
BOV
RFOF11
Fundo DE Investimento Im...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network